Recommendation of the President – Tolutris (telmisartan + amlodipine + hydrochlorothiazide)

On 20 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 141/2024 on the evaluation of the drug Tolutris (telmisartan + amlodipine + hydrochlorothiazide) for the indication: replacement therapy for the treatment of spontaneous blood pressure in adult patients whose blood pressure is adequately controlled during the concomitant use of combination medicinal products containing 2 active substances: telmisartan and hydrochlorothiazide, and medicinal products containing 1 active substance amlodipine, administered at the same doses as in combination, but in the form of separate tablets

Publication in Public Information Bulletin (BIP) >>